Background. Caspofungin (CAS) has recently been approved for treatment of invasive aspergillosis. In clinical trials, CAS-induced nephrotoxicity was markedly less pronounced compared to amphotericin B (AmB). Nevertheless, in a recent trial, nephrotoxicity in CAS-treated patients was considerably more pronounced than in preceding studies. Therefore, the aim of this study was to assess toxic effects of CAS on human renal proximal and distal tubular epithelial cells (PTC and DTC) in vitro, and to compare them to those of AmB. Methods. Cells were isolated from human kidney tissue, and exposed to clinically relevant concentrations of CAS and AmB for 24 h. Total DNA content and cell viability were determined by DAPI staining and a modified MTT assay. For testing of cytotoxicity, LDH activity was measured in cell culture supernatants. To assess apoptotic effects, AnnexinV-binding assay and DAPI staining for detection of fragmented DNA were performed. Results. DTC were more vulnerable towards the antifungal agents than PTC. In contrast to AmB, cell-damaging effects of CAS were less severe. DAPI staining revealed slight and dose-dependent antiproliferative effects of CAS at concentrations reflecting relevant plasma levels. At these concentrations, cell viability, determined by MTT assay, was not decreased in PTC and DTC. LDH release was marginally increased in a dose-dependent manner; apoptosis was not detected. Nevertheless, at CAS concentrations reflecting potential tissue concentrations, cell damaging effects were considerably more pronounced. Conclusion. Our results suggest that CAS is less nephrotoxic than AmB in vitro. The antiproliferative and cytotoxic effects of CAS predominantly affect DTC, which seem to be more susceptible to CASinduced damage.
Introduction
Caspofungin (CAS) is the first echinocandin that has recently been approved for treatment of mucosal and invasive candidiasis, and for second line treatment of aspergilllosis. It acts as an inhibitor of (1,3)-b-glucan synthesis, and therefore disturbs cell wall synthesis in many pathogenic fungi. Due to its selectivity towards fungal cell wall enzymes the side effects are, as far as it can be assessed at this point, moderate in humans [1] . Therefore, it is considered as a potential alternative to the highly nephrotoxic substance amphotericin B (AmB), which still constitutes the gold standard, especially regarding treatment of aspergillosis. Acute nephrotoxicity occurs in up to half of AmB-treated patients [2] .
Side effects of CAS assessed in clinical trials, particularly nephrotoxicity, were less severe compared to AmB. In these studies, which were carried out over an average of 14 days, nephrotoxicity was usually defined as an increase in serum creatinine, and ranged, in the majority of trials, from 0 to 1.4% [3] [4] [5] [6] .
Nevertheless, in one recent clinical trial, which compared CAS and AmB for treatment of invasive candidiasis, the rate of nephrotoxicity in the CAStreated group was higher than in previous studies, and comprised 8.4% [7] . These results might indicate that the nephrotoxic potential of CAS is higher than assumed. In the quoted studies nephrotoxicity was defined as an increase in serum creatinine, but it should be borne in mind that renal damage may occur before it is reflected in an elevation of serum creatinine. Phase I studies comparing CAS to AmB only looked at changes in serum creatinine and potassium levels. To our knowledge no renal histologies were obtained in these studies (MSD, personal communication) . Additionally, at the time of our study, data assessing extent and nature of CASassociated renal cell damage in vitro were not available. Considering these facts, the aim of our study was to characterize extent and nature of cell damaging effects of CAS in vitro, and to compare them to those of AmB. Due to the fact that AmB exerts direct toxic effects on renal tubular cells [8] , we selected proximal tubular cells (PTC) and distal tubular cells (DTC) for our experiments.
Subjects and methods

Cell culture
PTC and DTC were isolated with antibody-coated magnetic beads as previously described [9] . Briefly, cells were prepared after tumour nephrectomies from portions of the human kidney not involved in renal cell carcinoma. Tissue fragments were digested with collagenase/dispase (1 mg/ml; Boehringer Mannheim, Mannheim, Germany], collagenase IV (1 mg/ml; Gibco, Eggenstein, Germany), and DNase (100 mg/ml; Boehringer Mannheim). After Percoll density gradient centrifugation, cells were preincubated with human immunoglobulin G (2.5 mg/ml; Biotest, Dreieich, Germany), and afterwards incubated with the primary antibody. PTC were purified with a mouse-anti-human mAb against aminopeptidase M (CD13; Cymbus Biotechnology, Chandlers Ford, UK), specific for the proximal tubule. DTC were isolated with a mouse-anti-human mAb recognizing Tamm-Horsfall glycoprotein (purified supernatant from hybridoma, established in our laboratory), which is specific for the thick ascending limb of Henle's loop and the early distal convoluted tubule. Cells were incubated with a secondary, microbead-conjugated rat-anti-mouse anti-IgG 1 mAb (Miltenyi Biotec, Bergisch-Gladbach, Germany), and isolated by immunomagnetic separation applying a Mini-MACS system (Miltenyi Biotec).
Afterwards, PTC and DTC were seeded in 6-well plates precoated with human collagen IV (20 mg/ml; Boehringer Mannheim). Cells were grown in medium 199 (Gibco) with 10% FCS (PAA, Co¨lbe, Germany) at 37 C and 5% CO 2 in a humidified atmosphere. Preservation of differentiation and function of cultured tubular cells were tested as previously described [9, 10] .
Passages 3-5 of PTC and DTC were used for our experiments.
Exposure of PTC and DTC to antifungal agents PTC and DTC were grown in 8-, 12-and 96-well plates, and exposed to AmB (0.5, 2, 10, 30 mg/ml in glucose 5%; Bristol-Myers Squibb, Mu¨nchen, Germany), and to CAS (1, 2.5, 5, 10, 50 mg/ml in sodium chloride 0.9%; MSD Haar, Germany) for 24 h in medium 199 with 10% FCS. For testing of apoptosis, exposure to 0.25 and 0.5 mg/ml CAS, and exposure times of 1, 2 and 4 h were additionally assessed.
Testing for cell proliferation and viability
Determination of total DNA content with DAPI staining (Sigma, Deisenhofen, Germany) allows for an estimation of cell proliferation [11] . PTC and DTC were grown to 50% confluence. After 24 h exposure to CAS and AmB as described above, cells were washed three times with PBS. Lysis buffer [sodium dodecyl sulfate 0.02% (v/v); Biosource, Solingen, Germany] in 15 mM sodium citrate, and 0.15 M sodium chloride (ICN Biomedicals, Eschwege, Germany) and, after 15 min, DAPI (2 mg/ml) were added. Fluorescence was measured in a microplate reader (FLUOstar, BMG) at 460 nm after excitation at 355 nm.
Cell viability and proliferation were determined with a modified MTT assay (EZ4U; Biomedica, Vienna, Austria). The test is based on reduction of tetrazolium salts into red formazan derivatives in intact mitochondria of viable cells. After 24 h exposure of PTC and DTC to CAS and AmB, cells were washed three times with PBS. Tetrazolium salt solution was pipetted into each well as recommended by the manufacturer. After 3 h incubation, plates were measured in a microplate reader (Dynatech) at 450 nm.
Testing for cell necrosis
Necrotic damage leads to loss of cell integrity with consecutive release of intracellular lactate dehydrogenase (LDH) into the environment. LDH activity was measured in cell culture supernatants of PTC and DTC that were exposed to the antifungal agents as described above. LDH activity was determined by measuring the decrease of absorbance at 340 nm, resulting from conversion of NADH to NAD in the presence of pyruvate.
Testing for apoptosis
Translocation of the phospholipid phosphatidylserine from the inner to the outer leaflet of the cell membrane occurs during early apoptosis, and was detected by annexin V-binding (Annexin V-FITC Apoptosis Detection Kit I; BD Biosciences, Pharmingen, Germany). To assess membrane integrity, cells were additionally stained with propidium iodide (PI). PTC and DTC were grown to confluence in 12-well plates, and exposed to AmB and CAS for 1, 2, 4 and 24 h at concentrations stated above. For the positive control, cells were treated with 10 mM camptothecin for 24 h or with 250 ng/ml rapamycin for 1, 2 and 4 h. After exposure to the antifungal and proapoptotic substances, cells were washed twice with ice-cold PBS, and gently detached from culture wells with accutase (PAA, Co¨lbe, Germany). Cells and cell culture supernatants were centrifuged for 5 min at 300 g. The cell pellet was resuspended in annexin V-binding buffer (0.01 M HEPES-NaOH, pH 7.4, 0.14 M NaCl, 2.5 mM CaCl 2 ). We stained 100 ml of the cell suspension (10 6 cells/ml) with 5 ml annexin V-FITC and 5 ml PI. After incubation at room temperature for 15 min, 400 ml of annexin V-binding buffer were added, and a total of 10 000 cells per sample were analysed in a flow cytometer (Becton Dickinson). Data were evaluated with WinMDI software, version 2.8.
DNA fragmentation, which occurs in late apoptosis, was assessed after DAPI staining by fluorescence microscopy. Cells were grown to confluence on 8-well chamber slides, 2072 B. Wegner et al.
and treated with CAS and AmB for 1, 2, 4 and 24 h at concentrations stated above. Positive control cells were exposed to camptothecin and rapamycin as described above. After centrifugation at 300 g for 10 min, cells were washed three times with PBS, and fixed in acetone:methanol 1:1 (v/v) for 10 min. After washing with PBS, cells were stained with 2 mg/ml DAPI for 5 min. The number of apoptotic nuclei was determined by fluorescence microscopy, and related to the total number of cell nuclei. At least 300 nuclei were counted.
Statistical analysis
Results 
Results
In this section only data applying relevant plasma concentrations of CAS and AmB are illustrated in order to ensure clearness. Data of supratherapeutic, and potential tissue concentrations, are additionally depicted in Figure 1 -3 and Table 1 .
In order to determine cell proliferation, total amount of DNA was assessed by DAPI staining. DTC were grown in 96-well plates to 50% confluence, and exposed to clinically relevant concentrations of CAS and AmB for 24 h. Total DNA content per well was assessed by DAPI staining, and related to the DNA content per well of untreated cells. Data are expressed as mean reduction in DNA content in percent of control ± SEM. Each group of data was compared to the control group (n ¼ 4 Â 8 from four different cell isolations). *P < 0.05.
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Exposure to CAS and AmB caused a dose-dependent decrease in DNA content of PTC and DTC (expressed as percent of control) (Figures 1a and b) . In PTC exposed to CAS, decrease of DNA content was 6±1% of the control at the lowest concentration of 1 mg/ml (P<0.05), and 8±1% of the control at 2.5 mg/ml (P<0.05). AmB caused a decrease in DNA content of 5±1% at concentrations of 0.5 and 2 mg/ml (P<0.05).
The dose-dependent decrease in DNA content was significantly more prominent in DTC compared to PTC (P<0.05). In DTC, exposure to CAS at a concentration of 1 mg/ml induced a decrease in DNA content of 11±2% of the control (P<0.05) and, at a concentration of 2.5 mg/ml, of 14±2% of the control (P<0.005). AmB caused a decrease in DNA content of 16±2% of the control at 0.5 mg/ml (P<0.001), and of 22±2% of the control at 2 mg/ml (P<0.05).
Since measuring DNA content in lysed cells does not allow discrimination between living and dead cells, cell viability was determined with an MTT assay (Figures 2a and b) . In CAS-treated cells, statistically significant decreases in viability compared to control cells were only observed at concentrations of 50 mg/ml in PTC, and at concentrations !10 mg/ml in DTC, which might be associated with a lower test sensitivity or higher spreading of data. In AmB-treated cells, at concentrations !10 mg/ml in PTC, and !2 mg/ml in DTC, we observed statistically significant dosedependent decreases of viability. Exposure to 2 mg/ml AmB resulted in a decrease of viability of 4±3% of the control in PTC, and of 8±4% of the control (P<0.05) in DTC.
For further characterization of the nature of CASinduced damage, LDH activity was measured in cell culture supernatants. Exposure of PTC to CAS caused a moderate, dose-dependent increase of LDH release compared to the control group: Increases of LDH release of 7±7% of the control at 1 mg/ml, and of 17±8% of the control at 2.5 mg/ml were observed (Figure 3a) . In DTC, cytotoxic effects of CAS were more pronounced compared to PTC [CAS 1 mg/ml, 25±10% of the control; CAS 2.5 mg/ml, 29±11% of the control (Figure 3b) ]. Statistical significance of the LDH release data was achieved at CAS concentrations !10 mg/ml in both PTC and DTC. The dose-dependent increase in LDH release of AmB-treated cells was markedly more distinct than in CAS-10 treated cells (AmB 2 mg/ml; PTC, 157±9% of control; DTC, 203±11% of control; P<0.05], and reached, at supratherapeutic doses, values of 295±9% of the control (P<0.05) in PTC, and 527±12% of the control (P<0.05) in DTC. At CAS concentrations exceeding plasma concentrations, which reflect possible concentrations in renal tissue (>10 mg/ml), decreases of proliferation and viability, and increases of LDH release, were more pronounced (Figures 1-3) . Differences between PTC and DTC were statistically significant for results of DAPI staining and the LDH release assay (P<0.05). Differences of the MTT data between PTC and DTC were not statistically significant.
Testing for apoptosis with annexin V-binding revealed no significant apoptotic effects of AmB and CAS after exposure times of 1, 2, 4 and 24 h (Table 1 and Figure 4) . Likewise, after DAPI staining, no significant increase of DNA fragmentation was detected in CAS-and AmB-treated cells. With both assays we observed statistically significant apoptotic Fig. 3. (a and b) LDH release. (a) PTC and (b) DTC were grown in 12-well plates to 50% confluence, and exposed to clinically relevant concentrations of CAS and AmB for 24 h. As an indicator of cytotoxicity, LDH activity was measured in cell culture supernatants, and related to the LDH concentration of untreated cells. Data are expressed as mean increase in LDH release in percent of control ± SEM. Each group of data was compared to the control group (n ¼ 4 Â 4 from two different cell isolations). *P<0.05.
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effects in positive control PTC and DTC treated with the proapoptotic substances camptothecin and rapamycin with values around 350% of control cells (Table 2) .
Discussion
CAS is regarded as a potential alternative to AmB, especially in the treatment of systemic aspergillosis. Nevertheless, in one recent clinical study, the rate of nephrotoxicity in CAS-treated patients was higher than in previous studies [7] . At the time of our study, no in vitro data about CAS-induced cell damage were available. We analyzed CAS-induced renal damage in vitro in comparison with toxic effects of AmB, in order to assess an underestimation of the nephrotoxic potential of CAS. At concentrations reflecting therapeutic plasma concentrations, we detected moderate and dose-dependent antiproliferative and cytotoxic effects on PTC and DTC. At higher concentrations, which reflect potential tissue concentrations these effects were marked.
We tested CAS at concentrations between 1.0 and 50 mg/ml. In vivo, plasma peak levels are not likely to exceed 10 mg/ml [1] . Mean trough concentrations range between $1 and 2.5 mg/ml. Accumulation of the drug occurs after repeated applications due to its long half-life and non-linear pharmakokinetics. Two days after administration of CAS, >90% of the dose is found in tissues [12] . Hajdu et al. [13] have shown in a mouse model that the substance rapidly accumulates in tissues with 7-fold higher drug concentrations in the kidney compared to plasma concentrations. Thus, in vivo, PTC and DTC are likely to be exposed to CAS concentrations higher than plasma concentrations. Due to the fact that tissue concentrations have not been measured in humans, we can only assume that tubular cells are exposed to concentrations around 12 mg/ml. AmB was tested in our study at concentrations between 0.5 and 30 mg/ml. In vivo, mean therapeutic plasma levels range between 0.5 and 2 mg/ml. Immediately after administration of a single therapeutic dose of AmB, plasma levels peak to concentrations around 1.4 mg/ml, and drop very slowly to trough concentrations [14] . The substance, which is highly bound to proteins, has a long half-life of up to 48 h. For this reason, accumulation occurs after repeated applications. In summary, concentrations of 1-2.5 mg/ml CAS, and of 0.5-2 mg/ml AmB reflect relevant plasma concentrations.
After 24 h exposure to clinically relevant concentrations of AmB based on therapeutic plasma levels we detected pronounced and dose-dependent cell damaging effects on tubular cells, which were explicitly reflected in the LDH release assay. At supratherapeutic doses, impressive LDH release increases with values of up to 500% of the control were observed. In rabbit PTC, Joly et al. [15] demonstrated increases in LDH release after exposure to supratherapeutic a PTC and DTC were grown in 96-well plates to 50% confluence, and exposed to clinically relevant concentrations of CAS and AmB for 24 h. Total DNA content per well was assessed by (a) DAPI staining and, (b), cell viability was assessed by an MTT assay. AmB concentrations. Further studies, in which AmB toxicity was evaluated in vitro, showed results that were comparable to our findings [16, 17] . We did not detect significant apoptotic effects of AmB by means of annexin V and DAPI staining, even at low concentrations and short exposure times. These findings were not in concordance with in vitro results of Varlam et al. [16] , who have shown that AmB induces apoptosis in renal tubular cells at low concentrations of 1 and 2.5 mg/ml, and an exposure time of 1 h. However, due to the fact that in this study canine distal and porcine proximal tubular cells were used, we cannot compare our findings with these results offhand. Furthermore, it is known that substances that cause necrosis in renal tubular cells may exhibit apoptotic effects at low concentrations, and short exposure times [18] . The discrepancy of our findings might be caused by a higher sensitivity of human tubular cells towards AmB so that in our cells necrotic damage is observed at concentrations at which apoptotic effects are induced in tubular cells derived from other species. CAS-induced antiproliferative and cytotoxic effects at concentrations reflecting plasma concentrations were, in our study, less pronounced than in AmBtreated cells. Nevertheless, at concentrations exceeding plasma concentrations and representing potential tissue concentrations, these effects were considerably more pronounced. Further differentiation of the nature of damage pointed towards predominantly necrotic effects of CAS on PTC and DTC, reflected by data of the LDH release assay. No CAS-associated apoptotic effects were detected in PTC and DTC. Apoptosis and necrosis can represent two different mechanisms. On the other hand, as mentioned before, they might embody different grades of damage. In this case, apoptosis is characterized as an early and low-dose response, while necrosis appears as a late and highdose response. For these reasons we additionally tested for apoptosis at lower CAS concentrations (0.25 and 0.5 mg/ml), and at shorter exposure times (10 and 30 min) (data not shown). No apoptotic effects were detectable at these test conditions, hence we can assume that CAS does not induce apoptosis, even at short exposure times and low concentrations.
We can only speculate about mechanisms by which CAS damages tubular cells. The renal clearance of CAS is very low [1] ; nonetheless, Hajdu et al. [13] have demonstrated that CAS rapidly accumulates in animal kidney tissues. This observation allows the assumption that PTC and DTC, which have been shown to be vulnerable towards CAS in our in vitro studies, are indeed exposed to the substance at in vivo conditions. Considering the facts that CAS has a high molecular weight and is highly bound to serum albumin, it is not likely that the substance passes through the glomerular filter. We can assume that CAS initially reaches tubular cells via their basolateral membranes. Subsequently, in case of uptake into tubular cells and secretion of the substance into the tubular lumen, toxic effects might also be exerted via the luminal membrane. Regarding existing transport mechanisms in tubular cells, the extent of CAS-induced toxicity is likely to depend on distribution and amount of transporters that forward the echinocandin into or out of these cells, and thus have an impact on intracellular accumulation. CAS-associated tubular transport mechanisms have not been characterized yet, but considering the chemical structure of the lipopeptide CAS, organic anion transporters located at basolateral and luminal membranes of tubular cells might play an essential role. Due to the fact that CAS is not a substrate of glycoprotein P, trafficking of the substance via this transporter can be excluded [19] . The nature of AmB-associated renal cell damage is well described. The substance induces direct alterations in renal tubular cell membranes leading to the formation of transmembrane pores [8] . Tubular dysfunction with leakage of electrolytes is associated with these changes. Similarly to AmB, CAS might directly disrupt membrane integrity, initiating cascades involved in necrosis.
The proposed pathophysiological mechanisms are solely speculative. Further investigations are required in order to specify the mode of CAS-induced tubular cell damage.
We observed a different extent of CAS-associated damage in PTC compared to DTC. Except for the MTT data, our results suggest that DTC are significantly more vulnerable towards CAS than PTC. The pathomechanisms that stand behind these findings are unclear. However, it is known that different cell types display individual patterns of response to toxic agents due to differing cytokine and growth factor profiles. In a considerable number of studies, a higher sensitivity of DTC towards different toxic agents compared to PTC have been proven. Lash et al. [20] have shown that rat DTC in vitro were more vulnerable than rat PTC towards toxic damage induced by oxidants and alkylating agents targeting soft nucleophiles. As studies have shown, the increased vulnerability of DTC towards CAS gets aggravated in vivo by characteristic circumstances of these cells, namely exposition to higher sodium chloride concentrations and a lower pH environment compared to PTC [17] . In summary, our results suggest that CAS is less nephrotoxic than AmB in vitro. At concentrations reflecting plasma concentrations necrotic effects of CAS were moderate and predominantly affect DTC. Nevertheless, at concentrations that possibly represent tissue concentrations, antiproliferative and necrotic effects were markedly more pronounced so that the nephrotoxic potential of CAS should not be underestimated. Apoptotic effects do not seem to play a role in CAS-induced damage.
Subsequent studies, which specify pathomechanisms, protective conditions, and potential reversibility of CAS-induced tubular injury, are required to help develop strategies to prevent renal damage. Furthermore, longer clinical trials are needed for assessment of long term, CAS-associated renal damage. Nephrotoxitixity of the new antifungal agent CAS should be thoroughly assessed, in order to define its role as a superior alternative to AmB.
